Gilead Historical Cash Flow
| GILD Stock | USD 64.99 0.52 0.79% |
Analysis of Gilead Sciences cash flow over time is an excellent tool to project Gilead Sciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 3.5 B or Other Cashflows From Financing Activities of 2.3 B as it is a great indicator of Gilead Sciences ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Gilead Sciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Gilead Sciences is a good buy for the upcoming year.
Gilead |
About Gilead Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Gilead balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Gilead's non-liquid assets can be easily converted into cash.
Gilead Sciences Cash Flow Chart
Gilead Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Gilead Sciences Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
At present, Gilead Sciences' Other Cashflows From Financing Activities is projected to decrease significantly based on the last few years of reporting. The current year's Depreciation is expected to grow to about 2.8 B, whereas Change In Working Capital is projected to grow to (2.2 B). Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Gilead Sciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Gilead Sciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Gilead Sciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Gilead Sciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.At present, Gilead Sciences' Other Cashflows From Financing Activities is projected to decrease significantly based on the last few years of reporting. The current year's Depreciation is expected to grow to about 2.8 B, whereas Change In Working Capital is projected to grow to (2.2 B).
Gilead Sciences cash flow statement Correlations
Click cells to compare fundamentals
Gilead Sciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Gilead Sciences cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (6.3B) | (5.6B) | (659M) | 74M | 673M | 706.7M | |
| Free Cash Flow | 8.3B | 7.5B | 10.8B | 8.3B | 7.4B | 4.2B | |
| Change In Working Capital | (798M) | (1.6B) | 489M | (1.8B) | (2.3B) | (2.2B) | |
| Begin Period Cash Flow | 17.9B | 11.6B | 6.0B | 5.3B | 5.4B | 3.5B | |
| Other Cashflows From Financing Activities | (122M) | 8.0B | (145M) | (173M) | 1.7B | 2.3B | |
| Depreciation | 1.4B | 1.5B | 2.1B | 2.1B | 2.7B | 2.8B | |
| Other Non Cash Items | 4.6B | 7.8B | 2.1B | 5.1B | 2.2B | 2.3B | |
| Capital Expenditures | 825M | 650M | 579M | 728M | 585M | 614.3M | |
| Total Cash From Operating Activities | 9.1B | 8.2B | 11.4B | 9.1B | 8.0B | 4.5B | |
| Net Income | 5.4B | 89M | 6.2B | 4.6B | 5.6B | 3.0B | |
| Total Cash From Financing Activities | (7.6B) | 770M | (8.9B) | (6.5B) | (5.1B) | (4.9B) | |
| End Period Cash Flow | 11.6B | 6.0B | 5.3B | 5.4B | 6.1B | 3.7B | |
| Change To Inventory | (310M) | (95M) | (195M) | 11M | (842M) | (799.9M) | |
| Change To Liabilities | (178M) | (58M) | 207M | (1.1B) | (1.3B) | (1.2B) | |
| Stock Based Compensation | 636M | 643M | 635M | 637M | 766M | 422.3M | |
| Total Cashflows From Investing Activities | (7.8B) | (14.6B) | (3.1B) | (2.5B) | (2.3B) | (2.4B) | |
| Change To Account Receivables | (218M) | (1.2B) | 313M | (406M) | 157M | 164.9M | |
| Other Cashflows From Investing Activities | (4.7B) | (25.9B) | (3.1B) | (1.8B) | (1.6B) | (1.7B) | |
| Change To Netincome | (478M) | 6.5B | 11.4B | 3.5B | 4.0B | 4.2B | |
| Sale Purchase Of Stock | (1.7B) | (1.6B) | (546M) | (1.4B) | (1B) | (1.1B) | |
| Investments | (2.3B) | 11.9B | (3.1B) | (2.5B) | (1.9B) | (1.8B) | |
| Change Receivables | (218M) | (1.2B) | 313M | (406M) | (466.9M) | (490.2M) | |
| Net Borrowings | (2.8B) | 5.7B | (4.8B) | (1.5B) | (1.4B) | (1.3B) | |
| Dividends Paid | 3.2B | 3.4B | 3.6B | 3.7B | (3.8B) | (3.6B) | |
| Cash And Cash Equivalents Changes | (6.3B) | (5.7B) | (624M) | 137M | 123.3M | 229.1M | |
| Cash Flows Other Operating | 3.3B | 1.5B | 689M | 727M | 836.1M | 664.3M | |
| Change To Operating Activities | (696M) | 426M | 647M | (705M) | (634.5M) | (602.8M) | |
| Issuance Of Capital Stock | 209M | 256M | 169M | 309M | 382M | 295.9M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| CEOs Directory Screen CEOs from public companies around the world |
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Dividend Share 3.02 | Earnings Share 0.36 | Revenue Per Share 22 | Quarterly Revenue Growth 0.053 |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.